JP2017505348A5 - - Google Patents

Info

Publication number

JP2017505348A5

JP2017505348A5 JP2016568475A JP2016568475A JP2017505348A5 JP 2017505348 A5 JP2017505348 A5 JP 2017505348A5 JP 2016568475 A JP2016568475 A JP 2016568475A JP 2016568475 A JP2016568475 A JP 2016568475A JP 2017505348 A5 JP2017505348 A5 JP 2017505348A5

Authority

JP

Japan

Prior art keywords

composition

mast cell

cromolyn sodium

pulmonary

cell stabilizer

Prior art date

2015-02-09

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000203 mixture Substances 0.000 claims description 176
• 239000003381 stabilizer Substances 0.000 claims description 84
• 210000003630 histaminocyte Anatomy 0.000 claims description 75
• IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical group O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 claims description 74
• 229960000265 cromoglicic acid Drugs 0.000 claims description 70
• 208000019693 Lung disease Diseases 0.000 claims description 46
• 206010035664 Pneumonia Diseases 0.000 claims description 24
• 239000006199 nebulizer Substances 0.000 claims description 20
• 206010011224 Cough Diseases 0.000 claims description 18
• 210000004072 lung Anatomy 0.000 claims description 16
• 208000011580 syndromic disease Diseases 0.000 claims description 16
• 208000013116 chronic cough Diseases 0.000 claims description 14
• 206010006448 Bronchiolitis Diseases 0.000 claims description 12
• 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 12
• 230000008021 deposition Effects 0.000 claims description 12
• 201000000306 sarcoidosis Diseases 0.000 claims description 12
• 201000003883 Cystic fibrosis Diseases 0.000 claims description 8
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 8
• 201000009267 bronchiectasis Diseases 0.000 claims description 8
• 206010006451 bronchitis Diseases 0.000 claims description 8
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
• 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 8
• 230000000414 obstructive effect Effects 0.000 claims description 8
• 208000005069 pulmonary fibrosis Diseases 0.000 claims description 8
• 208000024891 symptom Diseases 0.000 claims description 8
• BLUGYPPOFIHFJS-UUFHNPECSA-N (2s)-n-[(2s)-1-[[(3r,4s,5s)-3-methoxy-1-[(2s)-2-[(1r,2r)-1-methoxy-2-methyl-3-oxo-3-[[(1s)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 BLUGYPPOFIHFJS-UUFHNPECSA-N 0.000 claims description 6
• 208000007934 ACTH-independent macronodular adrenal hyperplasia Diseases 0.000 claims description 6
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
• 229940112141 dry powder inhaler Drugs 0.000 claims description 5
• 208000032671 Allergic granulomatous angiitis Diseases 0.000 claims description 4
• 206010001881 Alveolar proteinosis Diseases 0.000 claims description 4
• 206010001889 Alveolitis Diseases 0.000 claims description 4
• 206010003757 Atypical pneumonia Diseases 0.000 claims description 4
• 208000003714 Bronchopulmonary Sequestration Diseases 0.000 claims description 4
• 206010006482 Bronchospasm Diseases 0.000 claims description 4
• 208000003417 Central Sleep Apnea Diseases 0.000 claims description 4
• 206010007982 Central-alveolar hypoventilation Diseases 0.000 claims description 4
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 4
• 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims description 4
• 208000025678 Ciliary Motility disease Diseases 0.000 claims description 4
• 208000021878 Congenital pulmonary sequestration Diseases 0.000 claims description 4
• 206010048768 Dermatosis Diseases 0.000 claims description 4
• 102000016942 Elastin Human genes 0.000 claims description 4
• 108010014258 Elastin Proteins 0.000 claims description 4
• 206010014561 Emphysema Diseases 0.000 claims description 4
• 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims description 4
• 206010016654 Fibrosis Diseases 0.000 claims description 4
• 208000015872 Gaucher disease Diseases 0.000 claims description 4
• 208000024869 Goodpasture syndrome Diseases 0.000 claims description 4
• 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 4
• 208000008745 Healthcare-Associated Pneumonia Diseases 0.000 claims description 4
• 208000031953 Hereditary hemorrhagic telangiectasia Diseases 0.000 claims description 4
• 208000021124 Heritable pulmonary arterial hypertension Diseases 0.000 claims description 4
• 101000801640 Homo sapiens Phospholipid-transporting ATPase ABCA3 Proteins 0.000 claims description 4
• 208000024934 IgG4-related mediastinitis Diseases 0.000 claims description 4
• 208000029523 Interstitial Lung disease Diseases 0.000 claims description 4
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
• 201000005099 Langerhans cell histiocytosis Diseases 0.000 claims description 4
• 208000032376 Lung infection Diseases 0.000 claims description 4
• 206010049459 Lymphangioleiomyomatosis Diseases 0.000 claims description 4
• 206010025219 Lymphangioma Diseases 0.000 claims description 4
• 208000001826 Marfan syndrome Diseases 0.000 claims description 4
• 208000037011 Microlithiasis Diseases 0.000 claims description 4
• 208000003019 Neurofibromatosis 1 Diseases 0.000 claims description 4
• 208000010577 Niemann-Pick disease type C Diseases 0.000 claims description 4
• 201000005702 Pertussis Diseases 0.000 claims description 4
• 102100033623 Phospholipid-transporting ATPase ABCA3 Human genes 0.000 claims description 4
• 108010007100 Pulmonary Surfactant-Associated Protein A Proteins 0.000 claims description 4
• 102000007620 Pulmonary Surfactant-Associated Protein C Human genes 0.000 claims description 4
• 108010007125 Pulmonary Surfactant-Associated Protein C Proteins 0.000 claims description 4
• 208000031467 Pulmonary capillary hemangiomatosis Diseases 0.000 claims description 4
• 208000019839 Pulmonary non-tuberculous mycobacterial infection Diseases 0.000 claims description 4
• 206010059160 Pulmonary sequestration Diseases 0.000 claims description 4
• 102100027773 Pulmonary surfactant-associated protein A2 Human genes 0.000 claims description 4
• 206010068690 Pulmonary vein occlusion Diseases 0.000 claims description 4
• 208000014777 Pulmonary venoocclusive disease Diseases 0.000 claims description 4
• REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 4
• 208000032056 Radiation Fibrosis Syndrome Diseases 0.000 claims description 4
• 206010067953 Radiation fibrosis Diseases 0.000 claims description 4
• 206010037765 Radiation pneumonitis Diseases 0.000 claims description 4
• 208000037656 Respiratory Sounds Diseases 0.000 claims description 4
• 206010057190 Respiratory tract infections Diseases 0.000 claims description 4
• 208000007930 Type C Niemann-Pick Disease Diseases 0.000 claims description 4
• 208000009470 Ventilator-Associated Pneumonia Diseases 0.000 claims description 4
• 206010047924 Wheezing Diseases 0.000 claims description 4
• 230000001154 acute effect Effects 0.000 claims description 4
• 201000009961 allergic asthma Diseases 0.000 claims description 4
• 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims description 4
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
• 208000006673 asthma Diseases 0.000 claims description 4
• 208000029771 childhood onset asthma Diseases 0.000 claims description 4
• 230000001684 chronic effect Effects 0.000 claims description 4
• 229940109248 cromoglycate Drugs 0.000 claims description 4
• 201000001981 dermatomyositis Diseases 0.000 claims description 4
• 201000010099 disease Diseases 0.000 claims description 4
• 208000035475 disorder Diseases 0.000 claims description 4
• 229920002549 elastin Polymers 0.000 claims description 4
• 201000009580 eosinophilic pneumonia Diseases 0.000 claims description 4
• 208000001780 epistaxis Diseases 0.000 claims description 4
• 208000024695 exercise-induced bronchoconstriction Diseases 0.000 claims description 4
• 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims description 4
• 230000004761 fibrosis Effects 0.000 claims description 4
• 206010020718 hyperplasia Diseases 0.000 claims description 4
• 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims description 4
• 201000010659 intrinsic asthma Diseases 0.000 claims description 4
• 239000008101 lactose Substances 0.000 claims description 4
• 230000036244 malformation Effects 0.000 claims description 4
• 206010063344 microscopic polyangiitis Diseases 0.000 claims description 4
• 230000035772 mutation Effects 0.000 claims description 4
• 206010028417 myasthenia gravis Diseases 0.000 claims description 4
• 201000003631 narcolepsy Diseases 0.000 claims description 4
• 208000011309 nasal bleeding Diseases 0.000 claims description 4
• 210000004412 neuroendocrine cell Anatomy 0.000 claims description 4
• 210000000056 organ Anatomy 0.000 claims description 4
• 208000005987 polymyositis Diseases 0.000 claims description 4
• 201000009266 primary ciliary dyskinesia Diseases 0.000 claims description 4
• 230000002685 pulmonary effect Effects 0.000 claims description 4
• 201000009732 pulmonary eosinophilia Diseases 0.000 claims description 4
• 230000000241 respiratory effect Effects 0.000 claims description 4
• 208000023504 respiratory system disease Diseases 0.000 claims description 4
• 208000007056 sickle cell anemia Diseases 0.000 claims description 4
• 208000017520 skin disease Diseases 0.000 claims description 4
• 230000007863 steatosis Effects 0.000 claims description 4
• 231100000240 steatosis hepatitis Toxicity 0.000 claims description 4
• 150000003431 steroids Chemical class 0.000 claims description 4
• 239000000126 substance Substances 0.000 claims description 4
• 230000009747 swallowing Effects 0.000 claims description 4
• 238000002054 transplantation Methods 0.000 claims description 4
• 201000008827 tuberculosis Diseases 0.000 claims description 4
• 230000009385 viral infection Effects 0.000 claims description 4
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
• 229930195725 Mannitol Natural products 0.000 claims description 3
• 238000009472 formulation Methods 0.000 claims description 3
• 239000000594 mannitol Substances 0.000 claims description 3
• 235000010355 mannitol Nutrition 0.000 claims description 3
• 239000011780 sodium chloride Substances 0.000 claims description 3
• UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 claims description 3
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
• RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 claims description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 2
• ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 claims description 2
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
• ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 claims description 2
• ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 2
• HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 2
• 239000000443 aerosol Substances 0.000 claims description 2
• 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 claims description 2
• MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 2
• 229960004958 ketotifen Drugs 0.000 claims description 2
• KDXKERNSBIXSRK-UHFFFAOYSA-M lysinate Chemical compound NCCCCC(N)C([O-])=O KDXKERNSBIXSRK-UHFFFAOYSA-M 0.000 claims description 2
• 239000011777 magnesium Substances 0.000 claims description 2
• 229910052749 magnesium Inorganic materials 0.000 claims description 2
• 229940071648 metered dose inhaler Drugs 0.000 claims description 2
• 229960004398 nedocromil Drugs 0.000 claims description 2
• RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 claims description 2
• 229960001783 nicardipine Drugs 0.000 claims description 2
• HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 2
• 229960001597 nifedipine Drugs 0.000 claims description 2
• 239000002245 particle Substances 0.000 claims description 2
• 229960001285 quercetin Drugs 0.000 claims description 2
• 235000005875 quercetin Nutrition 0.000 claims description 2
• -1 rhodoxamide Chemical compound 0.000 claims description 2
• 229940124818 soft mist inhaler Drugs 0.000 claims description 2
• 230000009885 systemic effect Effects 0.000 claims description 2
• 208000008589 Obesity Diseases 0.000 claims 9
• 210000004027 cell Anatomy 0.000 claims 9
• 235000020824 obesity Nutrition 0.000 claims 9
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
• 239000011574 phosphorus Substances 0.000 claims 1
• 229910052698 phosphorus Inorganic materials 0.000 claims 1
• 239000000843 powder Substances 0.000 claims 1
• 238000007670 refining Methods 0.000 claims 1
• 239000011734 sodium Substances 0.000 claims 1
• 229910052708 sodium Inorganic materials 0.000 claims 1
• 238000000034 method Methods 0.000 description 65
• 239000008213 purified water Substances 0.000 description 2
• 201000010549 croup Diseases 0.000 description 1